Melatonin treatment improves primary progressive multiple sclerosis: A case report

  • Antonio Lõpez-González
  • , Nuria Álvarez-Sánchez
  • , Patricia J. Lardone
  • , Ivan Cruz-Chamorro
  • , Alicia Martínez-Lõpez
  • , Juan M. Guerrero
  • , Russel J. Reiter
  • , Antonio Carrillo-Vico

Producción científica: Articlerevisión exhaustiva

56 Citas (Scopus)

Resumen

We describe the case of a female patient who, at the age of 28, was diagnosed with symptoms of primary progressive multiple sclerosis (PPMS). Glucocorticoid treatment was immediately initiated. The disease and the demyelinating lesions progressed during the following 9 years reaching Expanded Disability Status Scale (EDSS) 8.0 (patient essentially restricted to bed, a chair or perambulated in a wheelchair). At this point, the patient began taking melatonin at doses ranging from 50 to 300 mg per day. Melatonin was her only treatment for the next 4 years; during this interval, her EDSS progressively recovered to 6.0 (the person needs intermittent or unilateral constant assistance such as cane, crutch, or brace to walk 100 meters with or without resting). This long-lasting improvement is likely due to melatonin usage since it is related in time and because of its exceptionally long duration.

Idioma originalEnglish (US)
Páginas (desde-hasta)173-177
Número de páginas5
PublicaciónJournal of pineal research
Volumen58
N.º2
DOI
EstadoPublished - mar 2015

ASJC Scopus subject areas

  • Endocrinology

Huella

Profundice en los temas de investigación de 'Melatonin treatment improves primary progressive multiple sclerosis: A case report'. En conjunto forman una huella única.

Citar esto